Paroxysmal Nocturnal Hemoglobinuria

Comprehensive Clinical Guide: Paroxysmal Nocturnal Hemoglobinuria (PNH)

1. Introduction and Overview

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired, life-threatening hematologic disorder characterized by chronic intravascular hemolysis, bone marrow failure, and a high propensity for thrombosis. Unlike many hereditary hemolytic anemias, PNH is a clonal stem cell disorder resulting from a somatic mutation.

The name "Paroxysmal Nocturnal Hemoglobinuria" is historically descriptive, referring to the observation that patients often experienced dark-colored urine (hemoglobinuria) in the morning. However, this is a misnomer in modern clinical practice, as hemolysis occurs continuously 24 hours a day, and only a minority of patients report nocturnal exacerbations. PNH is essentially a disease of uncontrolled complement activation.

2. Etiology and Pathophysiology

The Genetic Trigger

The pathogenesis of PNH begins with a somatic mutation in the PIGA gene (Phosphatidylinositol Glycan class A), located on the X chromosome. This gene is essential for the synthesis of the glycosylphosphatidylinositol (GPI) anchor.

• The GPI Anchor: This protein serves as a "tether" that attaches various proteins to the surface of hematopoietic stem cells.
• The Consequence: When PIGA is mutated, the cell cannot produce GPI anchors. Consequently, key protective proteins—specifically CD55 (decay-accelerating factor) and CD59 (membrane inhibitor of reactive lysis)—are absent from the cell membrane.

Complement-Mediated Hemolysis

The absence of CD55 and CD59 leaves red blood cells (RBCs) defenseless against the host’s own complement system:
1. CD55: Inhibits C3 convertase, preventing the amplification of the complement cascade.
2. CD59: Inhibits the formation of the Membrane Attack Complex (MAC).

Without these regulators, complement proteins deposit on the RBC membrane, leading to the formation of the MAC, which punches holes in the RBC membrane, causing catastrophic intravascular lysis.

3. Clinical Presentation and Staging

PNH is a multisystem disease. While hemolysis is the hallmark, the morbidity is driven by thrombosis and marrow failure.

Standard Clinical Signs

Classification of PNH

Modern clinical practice classifies PNH based on the underlying bone marrow status:
1. Classic PNH: Evidence of PNH clone without bone marrow failure. High risk of thrombosis.
2. PNH in the setting of Bone Marrow Failure (BMF): PNH clone identified alongside Aplastic Anemia (AA) or Myelodysplastic Syndrome (MDS).
3. Subclinical PNH: Small PNH clones identified during routine testing for other marrow disorders.

4. Diagnostic Workup

The gold standard for diagnosis is High-Sensitivity Flow Cytometry.

Diagnostic Testing Protocol

• Flow Cytometry (Peripheral Blood): This is the definitive test. It assesses the presence of GPI-anchored proteins (CD55, CD59, FLAER) on erythrocytes, granulocytes, and monocytes.
• FLAER (Fluorescent Aerolysin): The most sensitive marker. FLAER binds specifically to the GPI anchor and is superior to CD55/CD59 staining.
• Complete Blood Count (CBC): Often reveals normocytic/macrocytic anemia and leukopenia/thrombocytopenia (if BMF is present).
• Lactate Dehydrogenase (LDH): A primary marker of hemolysis. Levels are typically 5–10 times the upper limit of normal.
• Iron Studies: Haptoglobin will be low; hemosiderinuria will be positive.

Differential Diagnosis

It is critical to distinguish PNH from conditions that mimic its symptoms:
* Autoimmune Hemolytic Anemia (AIHA): Detected via Direct Antiglobulin Test (Coombs). PNH is Coombs-negative.
* Hereditary Spherocytosis: Usually familial, negative for PNH clones.
* Aplastic Anemia: PNH clones may be present, but the primary pathology is hypocellular marrow.
* Thrombotic Thrombocytopenic Purpura (TTP): Presents with schistocytes and thrombocytopenia; ADAMTS13 activity is low.

5. Treatment Paradigms

Complement Inhibition

The introduction of monoclonal antibodies revolutionized PNH care.
* Eculizumab: A humanized monoclonal antibody that binds to C5, preventing the cleavage into C5a and C5b, thereby blocking the MAC.
* Ravulizumab: A long-acting C5 inhibitor, requiring less frequent dosing (every 8 weeks) compared to Eculizumab (every 2 weeks).
* Pegcetacoplan: A C3 inhibitor that provides proximal control of the complement cascade.

Supportive Care

• Anticoagulation: Prophylactic anticoagulation is generally not recommended for all patients, but it is mandatory for those with a history of thrombosis or very large PNH clones.
• Iron/Folate Supplementation: Essential for erythropoiesis.
• Allogeneic Stem Cell Transplant (HSCT): The only curative treatment, reserved for patients with severe bone marrow failure or poor response to complement inhibitors.

6. Risks, Contraindications, and Complications

Infectious Risks

Because complement inhibition (specifically C5 inhibitors) blocks the terminal complement pathway, patients are at a significantly increased risk of encapsulated bacterial infections, specifically Neisseria meningitidis.
* Mandatory Vaccination: All patients must be vaccinated against N. meningitidis (serogroups A, C, W, Y, and B) at least 2 weeks prior to therapy initiation.
* Prophylactic Antibiotics: Often prescribed during the first few weeks of therapy.

Contraindications

• Hypersensitivity: Known history of severe allergic reaction to the monoclonal antibody.
• Active, Unresolved Infection: Especially meningococcal infection.

7. Prognosis and Long-term Management

With the advent of complement inhibitors, the median survival of PNH patients has shifted from ~10–15 years to near-normal life expectancy. However, patients must be monitored for:
1. Breakthrough Hemolysis: Can occur if the dosing interval is missed or during severe systemic inflammation.
2. Malignant Transformation: A small percentage of PNH patients may develop Acute Myeloid Leukemia (AML).
3. Chronic Kidney Disease: Long-term damage from hemoglobin-induced oxidative stress requires ongoing nephrology monitoring.

8. Frequently Asked Questions (FAQ)

1. Is PNH a form of cancer?
PNH is a clonal stem cell disorder. While it is not a cancer in the traditional sense, it is a neoplastic process where a single mutated cell gains a growth advantage.

2. Why is urine dark in PNH patients?
The dark color is caused by hemoglobinuria—the presence of free hemoglobin in the urine, which is released when RBCs are destroyed in the bloodstream.

3. Does everyone with PNH need medication?
No. Patients with very small clones (<10%) and no symptoms may be managed with "watchful waiting."

4. How does Eculizumab work?
It acts as a "molecular shield" that stops the complement system from destroying red blood cells by blocking the C5 protein.

5. Can PNH be cured?
Currently, the only curative treatment is an allogeneic hematopoietic stem cell transplant, which carries significant risks.

6. Are PNH patients at higher risk of blood clots?
Yes. Thrombosis is the leading cause of death in untreated PNH. The risk is linked to the size of the PNH clone in granulocytes.

7. Why is the meningococcal vaccine so important?
Complement inhibitors disable the part of the immune system that kills Neisseria meningitidis. Without vaccination, the risk of life-threatening meningitis is extremely high.

8. Is PNH hereditary?
No. PNH is an acquired genetic mutation, not an inherited one. It cannot be passed from parent to child.

9. Can PNH cause erectile dysfunction?
Yes. The depletion of nitric oxide (caused by free hemoglobin) leads to smooth muscle spasms, which can cause both esophageal spasms and erectile dysfunction.

10. How often should I get my blood tested?
Patients on maintenance therapy typically require CBC, LDH, and reticulocyte counts every 3–6 months, depending on clinical stability.

9. Conclusion

Paroxysmal Nocturnal Hemoglobinuria remains a complex, multisystem disorder that requires a multidisciplinary approach involving hematology, nephrology, and infectious disease specialists. While the pathophysiology is rooted in a fundamental defect of the complement regulatory system, modern therapy has shifted the clinical focus from crisis management to long-term disease stabilization. Early diagnosis via high-sensitivity flow cytometry remains the most critical step in improving patient outcomes.

Disclaimer: This guide is for educational purposes only and does not constitute medical advice. Diagnosis and treatment should be conducted by qualified healthcare professionals.